Advanced Science, 2024 · DOI: 10.1002/advs.202305442 · Published: November 27, 2023
Spinal cord injury (SCI) often leads to inflammation, which worsens patient outcomes. This study found that a protein called Sting, which triggers inflammation, increases in microglia (immune cells in the brain and spinal cord) after SCI. The researchers discovered that Sting activation in microglia can worsen nerve damage after SCI. They also found that a protein called Mfn2, which is involved in mitochondrial function, is reduced in microglia after SCI. This reduction leads to the release of mitochondrial DNA (mtDNA), which then activates the Sting pathway. The scientists developed a nanoparticle to deliver a drug (MASM7) that increases Mfn2 levels. This treatment reduced inflammation and improved nerve function in mice with SCI, suggesting that targeting the Mfn2-mtDNA-Sting pathway could be a new way to treat SCI.
The Mfn2-mtDNA-cGas-Sting axis is identified as a potential therapeutic target for SCI treatment, offering new avenues for drug development.
The successful development of a biomimetic microglial nanoparticle (MSNs-MASM7@MI) provides a targeted drug delivery system for SCI treatment, enhancing drug efficacy and reducing side effects.
The study provides new insights into the mechanisms underlying secondary injuries in SCI, particularly the role of microglia, mitochondrial dysfunction, and the cGas-Sting pathway.